These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18587231)

  • 41. Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.
    Schlee S; Bollheimer LC; Bertsch T; Sieber CC; Härle P
    Z Gerontol Geriatr; 2018 Jul; 51(5):579-584. PubMed ID: 28233118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gout: a review of its aetiology and treatment.
    Li EK
    Hong Kong Med J; 2004 Aug; 10(4):261-70. PubMed ID: 15299172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Gouty encephalopathy: myth or reality?].
    Alla P; Carli P; Cellarier G; Paris JF; Chagnon A
    Rev Med Interne; 1997; 18(6):474-6. PubMed ID: 9247047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperuricemia and Gout in Orthopaedics.
    Meller M; Epstein A; Meller AY; Osmani FA; Parekh A; Chuang D; Gonzalez M
    JBJS Rev; 2018 Oct; 6(10):e11. PubMed ID: 30376463
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice].
    Fomin VV; Morosova TE; Tsurko VV
    Ter Arkh; 2019 Dec; 91(12):75-83. PubMed ID: 32598593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 48. Gout and hyperuricemia.
    Harris MD; Siegel LB; Alloway JA
    Am Fam Physician; 1999 Feb; 59(4):925-34. PubMed ID: 10068714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL; Macdonald PA; Hunt B; Jackson RL
    Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.
    Gast LF
    Clin Rheumatol; 1987 Mar; 6(1):70-3. PubMed ID: 3581700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Summary of the Dutch College of General Practitioners' "Gout" Standard].
    Romeijnders AC; Gorter KJ
    Ned Tijdschr Geneeskd; 2002 Feb; 146(7):309-13. PubMed ID: 11876034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 55. The modern management of gout.
    Rider TG; Jordan KM
    Rheumatology (Oxford); 2010 Jan; 49(1):5-14. PubMed ID: 19808695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Updates in the management of gout.
    Keith MP; Gilliland WR
    Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Managing your patient with gout: a review of treatment options.
    Doghramji PP
    Postgrad Med; 2011 May; 123(3):56-71. PubMed ID: 21566416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The medical/surgical management of gout.
    Landry JR; Schilero J
    J Foot Surg; 1986; 25(2):160-75. PubMed ID: 3519742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
    Pascual E; Sivera F
    Ann Rheum Dis; 2007 Aug; 66(8):1056-8. PubMed ID: 17223663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.